459 related articles for article (PubMed ID: 30943788)
41. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma.
Beygi S; Duran GE; Fernandez-Pol S; Rook AH; Kim YH; Khodadoust MS
Blood; 2022 Jun; 139(26):3732-3736. PubMed ID: 35436328
[TBL] [Abstract][Full Text] [Related]
42. An Elusive Case of Mycosis Fungoides: Case Report and Review of the Literature.
Pallazola VA; Deib G; Abha S; Geha RM; Kobayashi K
J Gen Intern Med; 2019 Nov; 34(11):2669-2674. PubMed ID: 31388911
[TBL] [Abstract][Full Text] [Related]
43. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches.
Weiner DM; Durgin JS; Wysocka M; Rook AH
J Am Acad Dermatol; 2021 Mar; 84(3):597-604. PubMed ID: 33352268
[TBL] [Abstract][Full Text] [Related]
44. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas.
Ribereau-Gayon E; Donzel M; Pham F; Romain-Scelle N; Perier-Muzet M; Balme B; Traverse-Glehen A; Ghesquières H; Dalle S
Leuk Lymphoma; 2023; 64(8):1424-1432. PubMed ID: 37255021
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of Brentuximab Vedotin in advanced cutaneous T-Cell lymphomas patients.
Papadavid E; Kapniari E; Marinos L; Nikolaou V; Oikonomidi A; Georgakopoulos J; Stratigos A; Kouloulias V; Pappa V
J Eur Acad Dermatol Venereol; 2019 May; 33(5):e223-e225. PubMed ID: 30821007
[No Abstract] [Full Text] [Related]
46. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry.
Muniesa C; Gallardo F; García-Doval I; Estrach MT; Combalia A; Morillo-Andújar M; De la Cruz-Vicente F; Machan S; Moya-Martínez C; Rovira R; Sanchez-Gonzalez B; Acebo E; Amutio E; Peñate Y; Losada-Castillo MDC; García-Muret MP; Iznardo H; Román-Curto C; Cañueto J; Fernández-de-Misa R; Flórez Á; Izu RM; Torres-Navarro I; Zayas A; Pérez-Paredes G; Blanes M; Yanguas JI; Pérez-Ferriols A; Callejas-Charavia M; Ortiz-Romero PL; Pérez-Gil A; Prieto-Torres L; González-Barca E; Servitje O
J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):57-64. PubMed ID: 36017748
[TBL] [Abstract][Full Text] [Related]
47. Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome.
Lewis DJ; Haun PL; Samimi SS; Vittorio CC; Villasenor-Park J; Barta SK; Landsburg DJ; Svoboda J; Nasta SD; Schuster SJ; Rook AH; Kim EJ
JAMA Dermatol; 2021 Mar; 157(3):317-321. PubMed ID: 33377934
[TBL] [Abstract][Full Text] [Related]
48. Brentuximab vedotin in CD30
Enos TH; Feigenbaum LS; Wickless HW
Int J Dermatol; 2017 Dec; 56(12):1400-1405. PubMed ID: 28762479
[TBL] [Abstract][Full Text] [Related]
49. Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study.
Suri A; Mould DR; Liu Y; Jang G; Venkatakrishnan K
Clin Pharmacol Ther; 2018 Nov; 104(5):989-999. PubMed ID: 29377077
[TBL] [Abstract][Full Text] [Related]
50. Management of refractory early-stage cutaneous T-cell lymphoma.
Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
[TBL] [Abstract][Full Text] [Related]
51. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
Kim YH; Tavallaee M; Sundram U; Salva KA; Wood GS; Li S; Rozati S; Nagpal S; Krathen M; Reddy S; Hoppe RT; Nguyen-Lin A; Weng WK; Armstrong R; Pulitzer M; Advani RH; Horwitz SM
J Clin Oncol; 2015 Nov; 33(32):3750-8. PubMed ID: 26195720
[TBL] [Abstract][Full Text] [Related]
52. Transformation of Sézary syndrome into CD30+ anaplastic large T-cell lymphoma after alemtuzumab therapy with evidence of clonal unity.
Nevet MJ; Zuckerman T; Sahar D; Bergman R
Am J Dermatopathol; 2015 Jan; 37(1):73-7. PubMed ID: 25548993
[TBL] [Abstract][Full Text] [Related]
53. A Case Series on the Use of Brentuximab Vedotin for the Treatment of Mycosis Fungoides.
Kelly KA; Edenfield L; Seegars MB; Vaidya R; Feldman SR; Strowd LC
J Drugs Dermatol; 2023 Dec; 22(12):e33-e34. PubMed ID: 38051830
[TBL] [Abstract][Full Text] [Related]
54. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
Kim YH; Prince HM; Whittaker S; Horwitz SM; Duvic M; Bechter O; Sanches JA; Stadler R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown LC; Ortiz-Romero PL; Akilov OE; Trotman J; Taylor K; Weichenthal M; Walewski J; Fisher D; McNeeley M; Gru AA; Brown L; Palanca-Wessels MC; Lisano J; Onsum M; Bunn V; Little M; Trepicchio WL; Dummer R
Eur J Cancer; 2021 May; 148():411-421. PubMed ID: 33794441
[TBL] [Abstract][Full Text] [Related]
55. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
[TBL] [Abstract][Full Text] [Related]
56. ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells.
Amatore F; Ortonne N; Lopez M; Orlanducci F; Castellano R; Ingen-Housz-Oro S; De Croos A; Salvado C; Gorvel L; Goubard A; Collette Y; Bouabdallah R; Schiano JM; Bonnet N; Grob JJ; Gaulard P; Bagot M; Bensussan A; Berbis P; Olive D
Blood Adv; 2020 Oct; 4(20):5203-5214. PubMed ID: 33095875
[TBL] [Abstract][Full Text] [Related]
57. Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease.
Argnani L; Broccoli A; Zinzani PL
Cancer Treat Rev; 2017 Dec; 61():61-69. PubMed ID: 29102679
[TBL] [Abstract][Full Text] [Related]
58. Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada.
Elsea D; Savage KJ; Lilley C; Lisano J; Liu J; Yu KS
Adv Ther; 2023 May; 40(5):2326-2338. PubMed ID: 36920744
[TBL] [Abstract][Full Text] [Related]
59. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
Lewis DJ; Rook AH
Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
[TBL] [Abstract][Full Text] [Related]
60. Cutaneous T-cell lymphomas-An update 2021.
Kempf W; Mitteldorf C
Hematol Oncol; 2021 Jun; 39 Suppl 1():46-51. PubMed ID: 34105822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
